| Title |
Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, August 2017
|
| DOI | 10.1007/s00259-017-3806-1 |
| Pubmed ID | |
| Authors |
Kyoichi Kaira, Tetsuya Higuchi, Ichiro Naruse, Yukiko Arisaka, Azusa Tokue, Bolag Altan, Satoshi Suda, Akira Mogi, Kimihiro Shimizu, Noriaki Sunaga, Takeshi Hisada, Shigehisa Kitano, Hideru Obinata, Takehiko Yokobori, Keita Mori, Masahiko Nishiyama, Yoshihito Tsushima, Takayuki Asao |
| Abstract |
Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in patients with previously treated non-small cell lung cancer. However, little is known about the established biomarker predicting the efficacy of nivolumab. Here, we conducted a preliminary study to investigate whether (18)F-FDG-PET/CT could predict the therapeutic response of nivolumab at the early phase. Twenty-four patients were enrolled in this study. (18)F-FDG-PET/CT was carried out before and 1 month after nivolumab therapy. SUVmax, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were calculated. Immunohistochemical analysis of PD-L1 expression and tumour-infiltrating lymphocytes was conducted. Among all patients, a partial metabolic response to nivolumab was observed in 29% on SUVmax, 25% on MTV, and 33% on TLG, whereas seven (29%) patients achieved a partial response (PR) based on RECIST v1.1. The predictive probability of PR (100% vs. 29%, p = 0.021) and progressive disease (100% vs. 22.2%, p = 0.002) at 1 month after nivolumab initiation was significantly higher in (18)F-FDG on PET/CT than in CT scans. Multivariate analysis confirmed that (18)F-FDG uptake after administration of nivolumab was an independent prognostic factor. PD-L1 expression and nivolumab plasma concentration could not precisely predict the early therapeutic efficacy of nivolumab. Metabolic response by (18)F-FDG was effective in predicting efficacy and survival at 1 month after nivolumab treatment. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 101 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 13% |
| Researcher | 13 | 13% |
| Other | 12 | 12% |
| Student > Master | 10 | 10% |
| Student > Bachelor | 8 | 8% |
| Other | 20 | 20% |
| Unknown | 25 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 50% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Agricultural and Biological Sciences | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Immunology and Microbiology | 3 | 3% |
| Other | 7 | 7% |
| Unknown | 29 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2017.
All research outputs
#21,153,429
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#2,610
of 3,083 outputs
Outputs of similar age
#279,192
of 318,835 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#28
of 39 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,835 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.